208 related articles for article (PubMed ID: 32226334)
1. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
Hu JK; Carlson K; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):41-44. PubMed ID: 32226334
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of rIFN-gamma in the treatment of lymphoma and melanoma of the skin by systemic and intralesional administration].
Jimbow K; Yamana K; Ishida O; Kawamura M; Ito Y; Maeda K
Gan To Kagaku Ryoho; 1987 Jan; 14(1):152-8. PubMed ID: 3099650
[TBL] [Abstract][Full Text] [Related]
3. Interventions for mycosis fungoides.
Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
[TBL] [Abstract][Full Text] [Related]
4. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement.
Doerschner M; Pekar-Lukacs A; Messerli-Odermatt O; Dommann-Scherrer C; Rütti M; Müller AM; Nair G; Kamarachev J; Kerl K; Beer M; Messerli M; Frauenknecht K; Haralambieva E; Hoetzenecker W; French LE; Guenova E
Br J Dermatol; 2019 Dec; 181(6):1296-1302. PubMed ID: 30565216
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of mycosis fungoides.
Galper SL; Smith BD; Wilson LD
Oncology (Williston Park); 2010 May; 24(6):491-501. PubMed ID: 20568590
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
7. Safe and efficacious use of intralesional steroids for the treatment of focally resistant mycosis fungoides.
Liu DY; Shaath T; Rajpara AN; Hanson C; Fraga G; Fischer R; Aires DJ
J Drugs Dermatol; 2015 May; 14(5):466-71. PubMed ID: 25942664
[TBL] [Abstract][Full Text] [Related]
8. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?
Papa G; Tura S; Mandelli F; Vegna ML; Defazio D; Mazza P; Zinzani PL; Simoni R; DePita O; Ferranti G
Br J Haematol; 1991 Oct; 79 Suppl 1():48-51. PubMed ID: 1931709
[TBL] [Abstract][Full Text] [Related]
9. Alteration of cytokine genes and bcl-2 expression following immunotherapy with intralesional IFN-gamma in a patient with tumor-stage mycosis fungoides.
Yamamoto T; Takahashi Y; Katayama I; Nishioka K
Dermatology; 1998; 196(3):283-7. PubMed ID: 9621132
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides.
Walker CJ; Espinosa ML; Mehta-Shah N; Pro B; Guitart J; Kuzel T
J Drugs Dermatol; 2021 Mar; 20(3):349-350. PubMed ID: 33683074
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
12. Update on skin directed therapies in mycosis fungoides.
Lovgren ML; Scarisbrick JJ
Chin Clin Oncol; 2019 Feb; 8(1):7. PubMed ID: 30525757
[TBL] [Abstract][Full Text] [Related]
13. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.
Wu PA; Huang V; Bigby ME
Br J Dermatol; 2014 May; 170(5):1015-20. PubMed ID: 24841586
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
15. Mycosis fungoides (CTCL) associated with colorectal adenocarcinoma. A rare case of combined response to neoadjuvant therapy.
Grimaldi L; Danzi R; Sivero L; De Capua M; Coppola A; Peltrini R; Mascolo M; Danzi M; Corcione F
Ann Ital Chir; 2021 Mar; 10():. PubMed ID: 33798118
[TBL] [Abstract][Full Text] [Related]
16. Total skin electron beam therapy in mycosis fungoides-a shift towards lower dose?
Chowdhary M; Song A; Zaorsky NG; Shi W
Chin Clin Oncol; 2019 Feb; 8(1):9. PubMed ID: 30525748
[TBL] [Abstract][Full Text] [Related]
17. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
18. CD45RA+ immunophenotype in mycosis fungoides: clinical, histological and immunophenotypical features in 22 patients.
Fierro MT; Novelli M; Savoia P; Cambieri I; Quaglino P; Osella-Abate S; Bernengo MG
J Cutan Pathol; 2001 Aug; 28(7):356-62. PubMed ID: 11437941
[TBL] [Abstract][Full Text] [Related]
19. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
Kowalzick L; Rogozinski T; Wimheuer R; Pilz J; Manske U; Scholz A; Fierlbeck G; Mohr P; Ochsendorf F; Wagner G; Gaus W; Brzoska J; Jablonska S
Eur J Dermatol; 2002; 12(6):558-61. PubMed ID: 12459527
[TBL] [Abstract][Full Text] [Related]
20. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
